HCW Biologics Inc. (HCWB )
Currency in USD Disclaimer
Subscribe Now for Delta3 AI Alerts
Don’t miss out on top stock picks and market insights. Subscribe to Delta3 AI Alerts for real-time updates and expert analysis straight to your inbox. Stay informed and maximize your investment potential.
Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
- Symbol HCWB
- Company HCW Biologics Inc.
- Price $1.22
- Changes Percentage 262.02
- Change 0.883
- Day Low $0.99
- Day High $1.42
- Year High $10
- Year Low $0.25
- Market Cap $2,544,732
- Price Avg 50 EMA (D) $0.45
- Price Avg 200 EMA (D) $2.19
- Exchange NASDAQ
- Volume 389,360,388
- Average Volume 9,326,008
- Open $1.11
- Previous Close $0.34
- EPS -10.63
- PE -0.11
- Earnings Announcement 2026-08-07 12:00:00
- Shares Outstanding $2,085,846
Company brief: HCW BIOLOGICS INC. (HCWB )
- Healthcare
- Biotechnology
- Dr. Hing C. Wong Ph.D.
- https://www.hcwbiologics.com
- US
- N/A
- 07-20-2021
- US40423R1059
HCW Biologics Inc., a preclinical stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases. The company's lead products include HCW9218, which is an injectable immunotherapeutic for patients with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as pulmonary fibrosis; and HCW9302 for auto-immune diseases, such as alopecia areata and metabolic diseases. It also develops HCW9201, a cell-based therapy that is in Phase II clinical trials for the treatment of patients with relapsed/refractory acute myeloid leukemia; and HCW9206 for the treatment of acute myeloid leukemia. The company was incorporated in 2018 and is headquartered in Miramar, Florida.
HCWB Corporation News
HCW Biologics Reports First Quarter 2026 Business Highlights and Financial Results
globenewswire.com -- MIRAMAR, Fla., May 14, 2026 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on developing transform...
HCW Biologics Discovers that HCW11-040 Prevents Bronchopulmonary Dysplasia (BPD) During IND-Enabling Studies
globenewswire.com -- HCW11-040 is a pembrolizumab-based fusion immunotherapeutic that activates immune cells and eliminates high-oxygen induced senescent cells...